Related references
Note: Only part of the references are listed.Anthracyclines in the treatment of HER2-negative breast cancer
Soonmyung Paik et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
HER2 and response to paclitaxel in node-positive breast cancer
Daniel F. Hayes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
GSK3β mediates suppression of cyclin D2 expression by tumor suppressor PTEN
W. Huang et al.
ONCOGENE (2007)
Essential role for nuclear PTEN in maintaining chromosomal integrity
Wen Hong Shen et al.
CELL (2007)
Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer
Christopher J. Poole et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells
Anjali Naresh et al.
CANCER RESEARCH (2006)
Observer variation in immunohistochemical analysis of protein expression, time for a change?
T. Kirkegaard et al.
HISTOPATHOLOGY (2006)
HER2 and responsiveness of breast cancer to adjuvant chemotherapy
KI Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group
AS Knoop et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
LM McShane et al.
BRITISH JOURNAL OF CANCER (2005)
Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5
MN Levine et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?
S Tovey et al.
CLINICAL CANCER RESEARCH (2005)
Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer
G Arpino et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Updated recommendations for HER2 testing in the UK
IO Ellis et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
GE Konecny et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
A Di Leo et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview
C Guillemette et al.
BREAST CANCER RESEARCH (2004)
Expression of the HERI-4 family of receptor tyrosine kinases in breast cancer
CJ Witton et al.
JOURNAL OF PATHOLOGY (2003)
The clinical evaluation of HER-2 status: which test to use?
J Bartlett et al.
JOURNAL OF PATHOLOGY (2003)
HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer
A Moliterni et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Evaluating HER2 amplification and overexpression in breast cancer
JMS Bartlett et al.
JOURNAL OF PATHOLOGY (2001)
HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide
A Di Leo et al.
ANNALS OF ONCOLOGY (2001)
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
S Paik et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
TAH Jarvinen et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
